M. Marty

8.9k total citations · 1 hit paper
128 papers, 6.3k citations indexed

About

M. Marty is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, M. Marty has authored 128 papers receiving a total of 6.3k indexed citations (citations by other indexed papers that have themselves been cited), including 81 papers in Oncology, 41 papers in Cancer Research and 21 papers in Molecular Biology. Recurrent topics in M. Marty's work include Cancer Treatment and Pharmacology (47 papers), Breast Cancer Treatment Studies (29 papers) and Colorectal Cancer Treatments and Studies (18 papers). M. Marty is often cited by papers focused on Cancer Treatment and Pharmacology (47 papers), Breast Cancer Treatment Studies (29 papers) and Colorectal Cancer Treatments and Studies (18 papers). M. Marty collaborates with scholars based in France, United States and Belgium. M. Marty's co-authors include Marc Espié, Jean Marc Extra, Fabien Calvo, Julie Gehl, Gregor Serša, Lluis M. Mir, Z Rudolf, Poul Geertsen, Chris Collins and Gerald C. O’Sullivan and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and The Journal of Immunology.

In The Last Decade

M. Marty

124 papers receiving 6.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Electrochemotherapy – An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study

2006 628 citations M. Marty et al. profile →

Peers

Countries citing papers authored by M. Marty

Since Specialization

Citations

This map shows the geographic impact of M. Marty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Marty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Marty more than expected).

Fields of papers citing papers by M. Marty

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Marty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Marty. The network helps show where M. Marty may publish in the future.

Co-authorship network of co-authors of M. Marty

This figure shows the co-authorship network connecting the top 25 collaborators of M. Marty. A scholar is included among the top collaborators of M. Marty based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Marty. M. Marty is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Transplantation-induced cancers: Emerging evidence that clonal CMV-specific NK cells are causal immunogenic factors 2014 ·OncoImmunology ·(unknown), Florence Baychelier, M. Marty, Patrice Debré, Didier Samuel, Vincent Vieillard	2
2	The impact of educational materials on compliance and persistence rates with adjuvant aromatase inhibitor treatment: First-year results from the Compliance of ARomatase Inhibitors AssessmenT In Daily practice through Educational approach (CARIATIDE) study 2014 ·The Breast ·Patrick Neven, Christos Markopoulos, Minna Tanner, M. Marty, R. Kreienberg, Lou Atkins, (unknown), Michael Gnant, Silvia P. Neciosup, Petra Tesařová, Sandro Barni, (unknown)	42
3	Estrogen receptor‐positive/human epidermal growth factor receptor 2‐negative breast tumors 2013 ·Cancer ·David Groheux, Mathieu Hatt, Elif Hindié, Sylvie Giacchetti, Patricia de Crémoux, Jacqueline Lehmann‐Che, Antoine Martineau, M. Marty, C. Cuvier, Catherine Cheze‐Le Rest, Anne de Roquancourt, Dimitris Visvikis, Marc Espié	47
4	Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab 2013 ·British Journal of Cancer ·(unknown), (unknown), Jacqueline Lehmann‐Che, Véronique Scott, (unknown), Bernard Asselain, J-Y Pierga, M. Marty, Patricia de Crémoux, F. Spyratos, Ivan Bièche	76
5	Challenging single- and multi-probesets gene expression signatures of pathological complete response to neoadjuvant chemotherapy in breast cancer: Experience of the REMAGUS 02 phase II trial 2013 ·The Breast ·Fabien Valet, Patricia de Crémoux, F. Spyratos, Nicolas Servant, (unknown), David Gentien, Jacqueline Lehmann‐Che, Véronique Scott, Brigitte Sigal‐Zafrani, (unknown), P Bertheau, Guinebretière Jm, Jean‐Yves Pierga, Suzette Delaloge, Sylvie Giacchetti, Étienne Brain, (unknown), M. Marty, Bernard Asselain	11
6	HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment 2013 ·British Journal of Cancer ·David Groheux, Sylvie Giacchetti, Mathieu Hatt, M. Marty, Laëtitia Vercellino, Anne de Roquancourt, C. Cuvier, Florence Coussy, Marc Espié, Elif Hindié	52
7	NF-kappa B genes have a major role in Inflammatory Breast Cancer 2008 ·BMC Cancer ·Florence Lerebours, Sophie Vacher, Catherine Andrieu, Marc Espié, M. Marty, Rosette Lidereau, Ivan Bièche	154
8	Predictive Factors of Outcome After Gastric Banding 2007 ·Annals of Surgery ·Jean‐Marc Chevallier, Michel Païta, Marie-Hélène Rodde-Dunet, M. Marty, (unknown), (unknown), Arnaud Basdevant	127
9	Decision making process in oncology practice: Is the information available and what should it consist of? 2005 ·Critical Reviews in Oncology/Hematology ·Jean Trédaniel, Jean‐Yves Blay, François Goldwasser, Bernard Asselain, Serge Koscielny, (unknown), (unknown), (unknown), Jean-Louis Misset, M. Marty	4
10	Molecular Profiling of Inflammatory Breast Cancer 2004 ·Clinical Cancer Research ·Ivan Bièche, Florence Lerebours, Sengül Tozlu, Marc Espié, M. Marty, Rosette Lidereau	188
11	Voyageurs français en Pologne durant la seconde moitié du XVIIIe siècle : écriture, Lumières et altérité 2004 ·Honoré Champion eBooks ·M. Marty	1
12	Reply 2004 ·Journal of Vascular Surgery ·Jean‐Baptiste Ricco, Olivier Goëau-Brissonnière, Marie-Hélène Rodde-Dunet, M. Marty, P Fender, H. Allemand, (unknown)	0
13	Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours 2003 ·Annals of Oncology ·Jaafar Bennouna, P. Fumoleau, P. Armand, Éric Raymond, Mario Campone, F.M. Delgado, C. Puozzo, M. Marty	71
14	Phase I clinical and pharmacokinetic studies of the taxoid derivative RPR 109881A administered as a 1-hour or a 3-hour infusion in patients with advanced solid tumors 2002 ·Annals of Oncology ·Cristiana Sessa, C. Cuvier, S. Caldiera, Jean Bauer, S. Van den Bosch, Christian Monnerat, Dorothée Sémiond, (unknown), (unknown), M Besenval, M. Marty	37
15	Évaluation des médicaments anticancéreux et apparentés : expériences et perspectives européennes et américaines 1999 ·Bulletin du Cancer ·Jean‐Charles Soria, M. Marty	1
16	Oxaliplatin added to 5-fluorouracil-based therapy (5-FU ± FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): Results from the European compassionate-use program 1999 ·Annals of Oncology ·S. Brienza, M.A. Bensmaïne, P Soulié, Christophe Louvet, Érick Gamelin, Éric François, Michel Ducreux, M. Marty, Thierry André, Filippo de Braud, Harry Bleiberg, (unknown), M. Itzhaki, Esteban Cvitkovic	45
17	Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group. 1996 ·Journal of Clinical Oncology ·R. Charles Coombes, Judith M. Bliss, J. Wils, F. Morvan, Marc Espié, D. Amadori, (unknown), MA Richards, Matti Aapro, (unknown), CS McArdle, Faustino R. Pérez‐López, P. Vassilopoulos, (unknown), C E Chilvers, Gill Coombes, E. Woods, M. Marty	129
18	Indices de qualité de vie pour l'évaluation des lombalgies. 1994 ·Revue du Rhumatisme ·(unknown), M. Marty	1
19	[Intraspinal paraganglioma. Apropos of 3 cases with a review of the literature]. 1990 ·PubMed ·(unknown), J Benezech, M. Marty, (unknown)	6
20	Phase I study of oxaliplatin in patients with advanced cancer 1990 ·Cancer Chemotherapy and Pharmacology ·Jean Marc Extra, Marc Espié, Fabien Calvo, Christophe Fermé, L. Mignot, M. Marty	295

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact